Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202508018 A randomized clinical trial to explore the impact of artifi cial intelligence electrocardiography on the management of ST-seg ment elevation myocardial infarction under a quality-based paymen t system New Medical Device NA
N202508040 An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT] New Drug Phase Ⅲ
N202508044 Performance Validation Report of Zinexts RNA Reagents for In Vitro Diagnostic (IVD) Device Registration New Medical Device NA
N202508081 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME New Drug Phase Ⅲ
N202508085 IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy New Drug Phase Ⅱ
N202508087 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) New Drug Phase Ⅲ
N202508094 KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) New Drug Phase Ⅱ
N202509001 A Randomized, Double-Blind, Placebo-Controlled Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of Stemis™ in Healthy Volunteers New Drug Phase Ⅰ
N202509014 Co-Developing an AI Model for Oocyte and Embryo Grading in and for Taiwan; thereafter Evaluating the Clinical Outcomes of combining an AI-Assisted Sperm Selection in conjunction with the above developed Oocyte Selection for ICSI for Taiwan New Medical Device NA
N202509034 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD) New Drug Phase Ⅲ
1 2 31 32 33 34 35 36 37 51 52 / 52

TOP